[
    [
        {
            "time": "",
            "original_text": "为节省挂牌相关成本与开支，药明康德同意控股子公司合全药业摘牌新三板",
            "features": {
                "keywords": [
                    "药明康德",
                    "合全药业",
                    "新三板",
                    "摘牌",
                    "成本",
                    "开支"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "为节省挂牌相关成本与开支，药明康德同意控股子公司合全药业摘牌新三板",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德：同意子公司合全药业申请股票终止挂牌",
            "features": {
                "keywords": [
                    "药明康德",
                    "合全药业",
                    "终止挂牌",
                    "股票"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德：同意子公司合全药业申请股票终止挂牌",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德：董事会同意控股子公司合全药业申请新三板终止挂牌",
            "features": {
                "keywords": [
                    "药明康德",
                    "董事会",
                    "合全药业",
                    "新三板",
                    "终止挂牌"
                ],
                "sentiment_score": -0.25,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德：董事会同意控股子公司合全药业申请新三板终止挂牌",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]